Wael Yassin Mansour

Dr. Wael Yassin Mansour is a dedicated cancer researcher at the University Medical Center Hamburg-Eppendorf, working within the Second Medical Clinic and Polyclinic. With a Dr.rer.nat. degree and over 40 publications spanning from 2008 to 2025, he has established himself as a significant contributor to the field of molecular oncology, particularly in DNA repair mechanisms and prostate cancer research. His work bridges fundamental molecular biology with clinical applications, making substantial contributions to understanding cancer biology and developing targeted therapies.

Dr. Mansour's research primarily focuses on DNA damage response pathways, homologous recombination repair deficiency in various cancers, and the development of targeted therapeutic approaches. His expertise spans from basic molecular mechanisms of DNA repair to translational applications in prostate cancer, head and neck cancer, and glioblastoma. He has made significant contributions to understanding how DNA repair deficiencies can be exploited therapeutically, particularly through PARP inhibitors and radiation sensitization approaches.

Analysis of his recent publications (2021-2025) reveals a strong emphasis on prostate cancer research, with particular focus on advanced therapeutic approaches for castration-resistant disease. His work integrates patient-derived models, molecular characterization of DNA repair defects, and development of novel targeted compounds. A significant portion of his research investigates the relationship between DNA repair pathways and response to radiation therapy, exploring how to enhance treatment efficacy through strategic targeting of repair mechanisms.

• Active researcher with continuous publication record from 2008-2025
• Specializes in DNA repair mechanisms and their clinical applications
• Key contributor to prostate cancer research at University Cancer Center Hamburg
• Extensive collaboration network within oncology research community

Dr. Mansour's research has significant implications for personalized cancer treatment, particularly in identifying patients who may benefit from targeted therapies based on their tumor's DNA repair profile. His work helps advance precision medicine approaches in oncology, potentially improving outcomes for patients with difficult-to-treat cancers.